Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer

被引：34

作者：

Yang, Chun ^{[1
]}

Croteau, Stephane ^{[2
]}

Hardy, Pierre ^{[1
]}

机构：

[1] Univ Montreal, CHU St Justine, Res Ctr, 3175 Cote Sainte Catherine,Room 2.17.004, Montreal, PQ H3T IC5, Canada

[2] Univ Montreal, Dept Med Pediat Pharmacol & Physiol, Montreal, PQ, Canada

来源：

CELLULAR ONCOLOGY | 2021年 / 44卷 / 05期

基金：

加拿大健康研究院;

关键词：

Histone deacetylase (HDAC) 9; Myocyte enhancer-binding factor 2-interacting transcriptional repressor (MITR); Tumorigenesis; Cancer development; Signaling pathways; CELL CARCINOMA GROWTH; GENE-EXPRESSION; DOWN-REGULATION; BREAST-CANCER; TRANSCRIPTIONAL CONTROL; MICRORNA-17-92; CLUSTER; PANCREATIC-CANCER; POOR-PROGNOSIS; T-CELLS; PROMOTES;

D O I：

10.1007/s13402-021-00626-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background HDAC9 (histone deacetylase 9) belongs to the class IIa family of histone deacetylases. This enzyme can shuttle freely between the nucleus and cytoplasm and promotes tissue-specific transcriptional regulation by interacting with histone and non-histone substrates. HDAC9 plays an essential role in diverse physiological processes including cardiac muscle development, bone formation, adipocyte differentiation and innate immunity. HDAC9 inhibition or activation is therefore a promising avenue for therapeutic intervention in several diseases. HDAC9 overexpression is also common in cancer cells, where HDAC9 alters the expression and activity of numerous relevant proteins involved in carcinogenesis. Conclusions This review summarizes the most recent discoveries regarding HDAC9 as a crucial regulator of specific physiological systems and, more importantly, highlights the diverse spectrum of HDAC9-mediated posttranslational modifications and their contributions to cancer pathogenesis. HDAC9 is a potential novel therapeutic target, and the restoration of aberrant expression patterns observed among HDAC9 target genes and their related signaling pathways may provide opportunities to the design of novel anticancer therapeutic strategies.

引用

页码：997 / 1017

页数：21

共 152 条

[1] Taxane benefit in breast cancer-a role for grade and chromosomal stability [J].

A'Hern, Roger P. ;

Jamal-Hanjani, Mariam ;

Szasz, A. Marcell ;

Johnston, Stephen R. D. ;

Reis-Filho, Jorge S. ;

Roylance, Rebecca ;

Swanton, Charles .

NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (06) :357-364

[2]

Adamska Aleksandra, 2018, Advances in Biological Regulation, V68, P77, DOI 10.1016/j.jbior.2017.11.007

[3] THE NUCLEOSOMAL CORE HISTONE OCTAMER AT 3.1-A RESOLUTION - A TRIPARTITE PROTEIN ASSEMBLY AND A LEFT-HANDED SUPERHELIX [J].

ARENTS, G ;

BURLINGAME, RW ;

WANG, BC ;

LOVE, WE ;

MOUDRIANAKIS, EN .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) :10148-10152

[4] Recent advances in class IIa histone deacetylases research [J].

Asfaha, Yodita ;

Schrenk, Christian ;

Avelar, Leandro A. Alves ;

Hamacher, Alexandra ;

Pflieger, Marc ;

Kassack, Matthias U. ;

Kurz, Thomas .

BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (22)

[5] Deficiency of the Stroke Relevant HDAC9 Gene Attenuates Atherosclerosis in Accord With Allele-Specific Effects at 7p21.1 [J].

Azghandi, Sepiede ;

Prell, Caroline ;

van der Laan, Sander W. ;

Schneider, Manuela ;

Malik, Rainer ;

Berer, Kerstin ;

Gerdes, Norbert ;

Pasterkamp, Gerard ;

Weber, Christian ;

Haffner, Christof ;

Dichgans, Martin .

STROKE, 2015, 46 (01) :197-+

[6] Histone Deacetylases 6 and 9 and Sirtuin-1 Control Foxp3+ Regulatory T Cell Function Through Shared and Isoform-Specific Mechanisms [J].

Beier, Ulf H. ;

Wang, Liqing ;

Han, Rongxiang ;

Akimova, Tatiana ;

Liu, Yujie ;

Hancock, Wayne W. .

SCIENCE SIGNALING, 2012, 5 (229)

[7] Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke [J].

Bellenguez, Celine ;

Bevan, Steve ;

Gschwendtner, Andreas ;

Spencer, Chris C. A. ;

Burgess, Annette I. ;

Pirinen, Matti ;

Jackson, Caroline A. ;

Traylor, Matthew ;

Strange, Amy ;

Su, Zhan ;

Band, Gavin ;

Syme, Paul D. ;

Malik, Rainer ;

Pera, Joanna ;

Norrving, Bo ;

Lemmens, Robin ;

Freeman, Colin ;

Schanz, Renata ;

James, Tom ;

Poole, Deborah ;

Murphy, Lee ;

Segal, Helen ;

Cortellini, Lynelle ;

Cheng, Yu-Ching ;

Woo, Daniel ;

Nalls, Michael A. ;

Mueller-Myhsok, Bertram ;

Meisinger, Christa ;

Seedorf, Udo ;

Ross-Adams, Helen ;

Boonen, Steven ;

Wloch-Kopec, Dorota ;

Valant, Valerie ;

Slark, Julia ;

Furie, Karen ;

Delavaran, Hossein ;

Langford, Cordelia ;

Deloukas, Panos ;

Edkins, Sarah ;

Hunt, Sarah ;

Gray, Emma ;

Dronov, Serge ;

Peltonen, Leena ;

Gretarsdottir, Solveig ;

Thorleifsson, Gudmar ;

Thorsteinsdottir, Unnur ;

Stefansson, Kari ;

Boncoraglio, Giorgio B. ;

Parati, Eugenio A. ;

Attia, John .

NATURE GENETICS, 2012, 44 (03) :328-U141

[8] Proteomic Analysis of Inflammatory Biomarkers Associated With Breast Cancer Recurrence [J].

Bera, Alakesh ;

Russ, Eric ;

Srinivasan, Muthu ;

Eidelman, Ofer ;

Eklund, Michael ;

Hueman, Matthew ;

Pollard, Harvey B. ;

Hu, Hai ;

Shriver, Craig D. ;

Srivastava, Meera .

MILITARY MEDICINE, 2020, 185 :669-675

[9] Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience [J].

Bezecny, Pavel .

MEDICAL ONCOLOGY, 2014, 31 (06)

[10] Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins [J].

Black, BL ;

Olson, EN .

ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 1998, 14 :167-196

← 1 2 3 4 5 6 7 8 9 10 →